Aug 25, 2009
Gloucester raises $29 million
Gloucester Pharmeceuticals Inc., (Cambridge, Mass) raised $29 million in a series D round led by new investor Novo A/S. Existing investors Apple Tree Partners; ProQuest Investments; Prospect Venture Partners; and Rho Ventures also participated.
Gloucester's romidepsin is under FRA review to treat cutaneous T cell lymphoma (CTCL) with a Nov.12 PDUFA date. The agency's Oncologic Drugs Advisory Committee will discuss the NDA for the histone deacetylase (HDAC) inhibitor on Sept.2. Novo's Thomas Dyrberg will join Gloucester's board.All news about Gloucester Pharmaceuticals